VCA Stocks

Inotek Pharmaceuticals Corporation nabs $19.3M.  Inotek has several products in development targeting oncology, cardiovascular, and inflammatory diseases. The Company’s lead program is focused on the development of potent oral and i.v. inhibitors of the nuclear enzyme poly (ADP-ribose) polymerase or PARP, which is in ongoing Phase 1b trials in oncology through Inotek’s 2006 partnership with Genentech.